Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: A population-based study

European Journal of Preventive Cardiology

Volumn 16, Issue 3, 2009, Pages 297-303

  Hansson, Jonas ^a   Lind, Lars ^a   Hulthe, Johannes ^b   Sundstrom, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

congestive; epidemiology; extracellular matrix; heart failure; left ventricular hypertrophy; population

Indexed keywords

ANTIHYPERTENSIVE AGENT; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; BODY HEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; GEOMETRY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAXATION TIME; SEX RATIO; SYSTOLIC BLOOD PRESSURE; VALVULAR HEART DISEASE; VASCULARIZATION;

AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 9; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 70349212099     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3283213108     Document Type: Article

References (28)

1. Sundstrom J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17: 45–53.
2. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 2004; 25: 1509–1516.
3. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham heart study. Circulation 2004; 109: 2850–2856.
4. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo CY, et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J 2007; 154: 291–297.
5. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535–540.
6. Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002; 15: 269–272.
7. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089–2096.
8. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136–141.
9. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89–96.
10. Coker ML, Zellner JL, Crumbley AJ, Spinale FG. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann N Y Acad Sci 1999; 878: 559.
11. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla H.R. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525–530.
12. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944–1949.
13. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728–1734.
14. Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hara Y, Shigematsu Y, et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-[alpha] in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 2003; 91: 1024–1027.
15. Sundstrom J, Arnlov J, Stolare K, Lind L. Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study. Heart 2008; 94: 874–878.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.
17. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ Jr, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708–1715.
18. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103: 2303–2309.
19. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002; 105: 753–758.
20. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002; 105: 1983–1988.
21. McElmurray JH Jr, Mukherjee R, New RB, Sampson AC, King MK, Hendrick JW, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther 1999; 291: 799.
22. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 1999; 85: 364–376.
23. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002; 54: 549–558.
24. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5: 1135–1142.
25. Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003; 284: H364–H371.
26. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39: 1384–1391.
27. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998; 82: 482–495.
28. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at −80°C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005; 338: 294–298.